We conclude that a significant percentage of urothelial carcinomas of the urinary bladder in patients from Pakistan show Her-2 overexpression raising the strong possibility of them being a potential target for anti-Her-2 therapy. This evidence concerns the gene ERBB2 and bladder transitional cell carcinoma.